As­cle­tis’ Gan­nex re­ports pos­i­tive in­ter­im PhII NASH da­ta af­ter scrap­ping pre­vi­ous mid-stage R&D plans

As­cle­tis’ sub­sidiary Gan­nex re­vealed that its non-al­co­holic steato­hep­ati­tis (NASH) drug can­di­date sig­nif­i­cant­ly re­duced av­er­age lev­els of liv­er fat in pa­tients en­rolled in a mid-stage tri­al, mark­ing a pos­i­tive mile­stone for the Chi­nese com­pa­ny.

Gan­nex’s Phase II study is in­ves­ti­gat­ing two dos­es of Gan­nex’s THR-be­ta ag­o­nist can­di­date ver­sus place­bo for 52 weeks and is ex­pect­ed to en­roll a to­tal of 180 NASH pa­tients.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER